MYO9B

Across TCGA pan-cancer cohorts, MYO9B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYO9B data layer compared with 28 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher MYO9B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYO9B expression acts as an unfavorable survival marker.

COAD, PDAC, and HNSC are the cancer types where MYO9B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Tertile	II,III,IV	0.792	1.000	.005	78	view →
PDAC	OS	Median	All	0.458	0.626	.007	36	view →
HNSC	DFS	Tertile	III,IV	0.453	0.860	<.001	19	view →
CCRCC	OS	Median	All	0.769	0.905	.026	7	view →
UCEC	DFS	Median	All	0.789	0.920	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MYO9B–COAD (DFS)

Open the COAD breakdown →